KR101241862B1 - 신규 ｇｌｐ-1 유도체 - Google Patents

신규 ｇｌｐ-1 유도체 Download PDF

Info

Publication number
KR101241862B1
KR101241862B1 KR1020067005530A KR20067005530A KR101241862B1 KR 101241862 B1 KR101241862 B1 KR 101241862B1 KR 1020067005530 A KR1020067005530 A KR 1020067005530A KR 20067005530 A KR20067005530 A KR 20067005530A KR 101241862 B1 KR101241862 B1 KR 101241862B1
Authority
KR
South Korea
Prior art keywords
ethoxy
glp
lys
aib
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067005530A
Other languages
English (en)
Korean (ko)
Other versions
KR101241862B9 (ko
KR20060096997A (ko
Inventor
제스퍼 라우
토마스 크루스 한센
킬드 매드슨
포우 블로크
플로렌시오 자라고자 도르왈드
닐스 란겔란드 조한슨
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20060096997A publication Critical patent/KR20060096997A/ko
Application granted granted Critical
Publication of KR101241862B1 publication Critical patent/KR101241862B1/ko
Publication of KR101241862B9 publication Critical patent/KR101241862B9/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067005530A 2003-09-19 2004-09-17 신규 ｇｌｐ-1 유도체 Expired - Lifetime KR101241862B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200301367 2003-09-19
DKPA200301367 2003-09-19
US50573903P 2003-09-25 2003-09-25
US60/505,739 2003-09-25
US52684703P 2003-12-04 2003-12-04
DKPA200301789 2003-12-04
US60/526,847 2003-12-04
DKPA200301789 2003-12-04
PCT/DK2004/000624 WO2005027978A2 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides

Publications (3)

Publication Number Publication Date
KR20060096997A KR20060096997A (ko) 2006-09-13
KR101241862B1 true KR101241862B1 (ko) 2013-03-13
KR101241862B9 KR101241862B9 (ko) 2022-12-09

Family

ID=46045404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067005530A Expired - Lifetime KR101241862B1 (ko) 2003-09-19 2004-09-17 신규 ｇｌｐ-1 유도체

Country Status (13)

Country Link
US (6) US20070203058A1 (enrdf_load_stackoverflow)
EP (2) EP2932981B1 (enrdf_load_stackoverflow)
JP (1) JP4949838B2 (enrdf_load_stackoverflow)
KR (1) KR101241862B1 (enrdf_load_stackoverflow)
AU (2) AU2004273573B2 (enrdf_load_stackoverflow)
BR (2) BR122019021416A2 (enrdf_load_stackoverflow)
CA (1) CA2539253A1 (enrdf_load_stackoverflow)
IL (1) IL174154A (enrdf_load_stackoverflow)
MX (1) MXPA06002941A (enrdf_load_stackoverflow)
NO (1) NO343825B1 (enrdf_load_stackoverflow)
SI (1) SI2932981T1 (enrdf_load_stackoverflow)
TW (1) TW200526254A (enrdf_load_stackoverflow)
WO (1) WO2005027978A2 (enrdf_load_stackoverflow)

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005089722A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2005247369A1 (en) 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
EP1784427A2 (en) 2004-06-01 2007-05-16 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
EP1765408B1 (en) 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
KR20070094909A (ko) 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
ES2361095T5 (es) 2005-05-04 2021-11-23 Zealand Pharma As Análogos del péptido 2 tipo glucagón (GLP-2)
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
CN100429227C (zh) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1954313A1 (en) * 2005-11-01 2008-08-13 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
CN101534846B (zh) * 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
EP1963343A1 (en) 2005-12-14 2008-09-03 Novo Nordisk A/S Polypeptide protracting tags
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
MX2008010136A (es) * 2006-02-08 2008-12-19 Lonza Ag Sintesis de peptidos similares al glucagon.
WO2007104789A2 (en) * 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
MX2009004701A (es) 2006-11-08 2009-05-21 Zealand Pharma As Analogos selectivos del peptido 2 similar al glucagon.
JP2010043001A (ja) * 2006-11-09 2010-02-25 Sanwa Kagaku Kenkyusho Co Ltd Ｇｌｐ−１誘導体とその用途
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2009012502A1 (en) * 2007-07-19 2009-01-22 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Self- anchoring mems intrafascicular neural electrode
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
JP2010538049A (ja) * 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
ES2532116T3 (es) * 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2234644B1 (en) * 2008-01-04 2013-07-31 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
WO2009115525A2 (en) * 2008-03-20 2009-09-24 N.V. Organon Preparation of a pharmaceutical composition for increasing bone mineral density
BRPI0909397A2 (pt) 2008-03-31 2015-12-15 Glaxo Group Ltd composição, uso de uma composição, formulação, dispositivo de liberação, ácido nucléico, vetor, célula hospedeira, e, métodos para produzir um polipeptídeo de fusão
CN102989001B (zh) 2008-04-29 2014-12-03 阿森迪斯药物生长障碍股份有限公司 Peg化的重组人生长激素化合物
RU2504550C2 (ru) * 2008-05-16 2014-01-20 Ново Нордиск А/С Длительно действующие агонисты рецепторов y2 и(или) y4
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
ES2579502T3 (es) 2008-06-17 2016-08-11 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
HUE028072T2 (en) * 2008-06-17 2016-11-28 Univ Indiana Res & Tech Corp GIP-based agonists for the treatment of metabolic disease and obesity
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
RU2526804C2 (ru) * 2008-08-06 2014-08-27 Ново Нордиск Хелс Кеа Аг Конъюгированные белки с пролонгированным действием in vivo
ES2662501T3 (es) 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
EA026508B1 (ru) 2008-12-05 2017-04-28 Глэксо Груп Лимитед Единичный вариабельный домен иммуноглобулина и выделенный устойчивый к протеазе полипептид, связывающие сывороточный альбумин человека
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
JP5755566B2 (ja) 2008-12-19 2015-07-29 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
US20110237493A1 (en) * 2008-12-19 2011-09-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
MA33221B1 (fr) 2009-03-27 2012-04-02 Glaxo Group Ltd Fusions de médicament et conjugués afférents
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011015649A1 (en) * 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
EP2493919A1 (en) 2009-10-30 2012-09-05 Novo Nordisk A/S Derivatives of cgrp
JP2013510829A (ja) * 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
DK2513140T3 (en) 2009-12-16 2016-01-18 Novo Nordisk As Double-acylated GLP-1 derivatives
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
WO2011089255A1 (en) * 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
US20130012684A1 (en) * 2010-02-16 2013-01-10 Novo Nordisk A/S Purification Method
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
US20130143798A1 (en) * 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
AU2011247824B2 (en) * 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP6069198B2 (ja) * 2010-07-20 2017-02-01 ノヴォ ノルディスク アー／エス Ｎ末端が修飾されたｆｇｆ２１化合物
MX351128B (es) 2010-09-28 2017-10-03 Aegerion Pharmaceuticals Inc Polipeptidos manipulados que tienen duracion de accion incrementada.
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
KR20130141648A (ko) * 2011-01-26 2013-12-26 노보 노르디스크 에이/에스 렙틴 유도체
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
KR101496136B1 (ko) 2011-03-30 2015-02-26 베타 파머수티컬 컴퍼니 리미티드 글루카곤 유사 펩타이드-1 유사체 및 이의 용도
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
HRP20170890T1 (hr) 2011-06-22 2017-09-08 Indiana University Research And Technology Corporation Suagonisti glukagonskog/glp-1 receptora
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2729481B1 (en) * 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104244981A (zh) 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
ES2682253T3 (es) 2011-12-29 2018-09-19 Novo Nordisk A/S Dipéptido que comprende un aminoácido no proteogénico
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
SG10201606783RA (en) 2012-02-15 2016-10-28 Amunix Operating Inc Factor viii compositions and methods of making and using same
CA3179537A1 (en) 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
PL3542790T3 (pl) 2012-03-22 2024-02-26 Novo Nordisk A/S Kompozycje zawierające substancję dostarczającą i ich przygotowanie
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
EP2846824B1 (en) 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP2849775A1 (en) 2012-05-16 2015-03-25 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
MX2014015558A (es) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
EP4406593A3 (en) 2012-07-01 2024-10-23 Novo Nordisk A/S Use of long-acting glp-1 peptides
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
JP2016500682A (ja) 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
IN2015DN03795A (enrdf_load_stackoverflow) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
CN103217522A (zh) * 2013-03-18 2013-07-24 中国人民解放军第四军医大学 一种采用消化法消化提取细胞流式检测组织内细胞凋亡率的方法
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2991671B1 (en) 2013-05-02 2018-08-15 Novo Nordisk A/S Oral dosing of glp-1 compounds
KR20160021183A (ko) * 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
EP3013370A1 (en) * 2013-06-24 2016-05-04 Riogin Corporation Double binding constructs
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
JP6599863B2 (ja) 2013-08-15 2019-10-30 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
AU2014345511A1 (en) * 2013-11-11 2016-05-12 Ascendis Pharma A/S Relaxin prodrugs
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN103985909B (zh) * 2014-05-14 2016-08-24 山东爱通工业机器人科技有限公司 一种锂电池电池片组左右两侧面贴胶装置
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR20230152187A (ko) 2014-11-18 2023-11-02 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
HRP20211734T8 (hr) 2014-11-21 2022-03-04 Ascendis Pharma Endocrinology Division A/S Dozni oblici dugodjelujućeg hormona rasta
ES2739289T3 (es) * 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
JP6691125B2 (ja) * 2014-12-17 2020-04-28 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
KR102427527B1 (ko) 2014-12-23 2022-08-01 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
KR102476550B1 (ko) 2015-06-12 2022-12-13 노보 노르디스크 에이/에스 선택적인 pyy 화합물 및 그것의 사용
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
HK1254461A1 (zh) 2015-09-22 2019-07-19 加利福尼亚大学董事会 經修飾的細胞毒素及其治療用途
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017083604A1 (en) * 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
RS66250B1 (sr) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases As Prolekovi pth
EP3484523A1 (en) 2016-07-13 2019-05-22 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
MA46345A (fr) 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases As Composés de pth ayant un faible rapport entre le pic et le niveau minimum
KR20240013849A (ko) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
PT3518982T (pt) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Descoberta da dose incremental em compostos de pth de libertação controlada
IL290054B2 (en) 2016-09-29 2024-03-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US10913952B2 (en) * 2016-10-26 2021-02-09 Salk Institute For Biological Studies Environmental stress response transcriptional regulatory network
MA46967A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
IL267224B2 (en) 2016-12-16 2023-10-01 Novo Nordisk As Insulin containing pharmaceutical compositions
EP4424362A3 (en) 2017-06-16 2024-11-27 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CN111050750B (zh) 2017-08-24 2024-09-24 诺和诺德股份有限公司 Glp-1组合物及其用途
JP7148605B2 (ja) 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
WO2019178462A1 (en) 2018-03-16 2019-09-19 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
JP7526716B2 (ja) 2018-03-23 2024-08-01 カーモット セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体の調節剤
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
IL308797A (en) 2018-03-28 2024-01-01 Ascendis Pharma Oncology Div A/S Il-2 conjugates
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
JP7442823B2 (ja) 2018-04-06 2024-03-05 シプルメット・ゲーエムベーハー 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
DK3793587T3 (da) 2018-05-18 2025-07-21 Ascendis Pharma Bone Diseases As Startdosis af pth-konjugater
SG11202011838XA (en) * 2018-05-31 2020-12-30 Univ Hong Kong Polytechnic Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
PH12021551906A1 (en) 2019-02-11 2022-08-01 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
MX2021010286A (es) 2019-03-04 2021-09-23 Ascendis Pharma Endocrinology Div A/S Formas de dosificacion de la hormona del crecimiento de accion prolongada con eficacia superior a la somatropina diaria.
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
SG11202111281TA (en) 2019-05-21 2021-12-30 Novartis Ag Cd19 binding molecules and uses thereof
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
BR112022022826A2 (pt) 2020-06-03 2022-12-13 Ascendis Pharma Oncology Div A/S Sequências de il-2 e usos das mesmas
MX2023002047A (es) 2020-08-28 2023-03-15 Ascendis Pharma Oncology Div A/S Proteinas de interleucina 2 (il-2) glucosiladas y usos de las mismas.
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
AU2021349316A1 (en) 2020-09-28 2023-04-27 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP2023545684A (ja) * 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
TW202440619A (zh) 2020-12-18 2024-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
JP7604666B2 (ja) 2021-01-20 2024-12-23 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
MX2023011059A (es) 2021-04-01 2023-09-29 Ascendis Pharma As Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
WO2022241287A2 (en) 2021-05-13 2022-11-17 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
WO2022268213A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含glp-1化合物的药物组合物
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
CN116848243B (zh) 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法
CN120225181A (zh) 2022-09-30 2025-06-27 延伸生物科学股份有限公司 长效甲状旁腺激素
AU2023374533A1 (en) 2022-11-02 2025-04-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
AU2023415591A1 (en) 2022-12-30 2025-08-14 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025024455A1 (en) 2023-07-24 2025-01-30 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043361A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP1498425A1 (en) 1986-05-05 2005-01-19 The General Hospital Corporation Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
WO1990011296A1 (en) * 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2000517308A (ja) * 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002504518A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003519664A (ja) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
ATE437891T1 (de) * 2000-12-07 2009-08-15 Lilly Co Eli Glp-1 fusionsproteine
FR2819810B1 (fr) * 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
DK1412384T3 (da) * 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
EP1423136A4 (en) * 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
EA200401345A1 (ru) * 2002-04-10 2005-08-25 Эли Лилли Энд Компани Лечение гастропареза
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
WO2010029159A1 (en) * 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043361A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Also Published As

Publication number Publication date
IL174154A (en) 2013-09-30
EP2932981A3 (en) 2016-02-24
IL174154A0 (en) 2006-08-01
JP4949838B2 (ja) 2012-06-13
EP2932981B1 (en) 2021-06-16
TW200526254A (en) 2005-08-16
BRPI0414539B8 (pt) 2021-05-25
BR122019021416A2 (enrdf_load_stackoverflow) 2019-12-21
US20160108102A1 (en) 2016-04-21
US20130040884A1 (en) 2013-02-14
US20100305032A1 (en) 2010-12-02
AU2004273573A1 (en) 2005-03-31
BRPI0414539A (pt) 2006-11-07
US20130244931A1 (en) 2013-09-19
AU2004273573B2 (en) 2010-04-22
MXPA06002941A (es) 2006-05-31
EP1670515A2 (en) 2006-06-21
US20130053315A1 (en) 2013-02-28
NO20061722L (no) 2006-06-12
US20070203058A1 (en) 2007-08-30
CA2539253A1 (en) 2005-03-31
WO2005027978A2 (en) 2005-03-31
NO343825B1 (no) 2019-06-17
AU2010203063A1 (en) 2010-08-12
SI2932981T1 (sl) 2021-11-30
EP2932981A2 (en) 2015-10-21
KR101241862B9 (ko) 2022-12-09
JP2007505840A (ja) 2007-03-15
KR20060096997A (ko) 2006-09-13
WO2005027978A3 (en) 2005-05-19
AU2010203063B2 (en) 2012-10-25
BRPI0414539B1 (pt) 2020-12-29

Similar Documents

Publication Publication Date Title
KR101241862B1 (ko) 신규 ｇｌｐ-1 유도체
US8536122B2 (en) Acylated GLP-1 compounds
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
EP2190460B1 (en) Peptides derivatized with a-b-c-d- and their therapeutical use
JP5476304B2 (ja) グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
CN100444898C (zh) 治疗肽的清蛋白结合型衍生物
US20090062192A1 (en) Dimeric Peptide Agonists of the Glp-1 Receptor
US20090005312A1 (en) Novel glp-1 analogues linked to albumin-like agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090914

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110819

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120731

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130129

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130305

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130306

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160218

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220223

Start annual number: 10

End annual number: 10

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20220726

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20220830

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20130305

Patent event code: PJ02021E01I

Appeal kind category: Correction

Request date: 20220830

Appeal identifier: 2022105000076

J301 Trial decision

Free format text: TRIAL NUMBER: 2022105000076; TRIAL DECISION FOR CORRECTION REQUESTED 20220830

Effective date: 20221021

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20221021

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20220830

Decision date: 20221021

Appeal identifier: 2022105000076

PG1701 Publication of correction

Publication date: 20221209

PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 12

End annual number: 12